Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant764 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,475 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03079687 | Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | approved for marketing | — | — | AstraZenecaINDUSTRY | 1 | Oct 25, 2017 | clinicaltrials |
| NCT03025867 | Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer | approved for marketing | — | — | Tesaro, Inc.INDUSTRY | 0 | Apr 17, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Oct 25, 2017source: clinicaltrials